Astellas Pharma Inc

astellas.com

Total trials

523

Active

7

Phase 3

146

Total enrollment

182,147

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 26 of 26 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
avacincaptad pegol1
Gilteritinib3
Cytarabine2
Mitoxantrone1
Etoposide1
G-CSF1
Fludarabine1
ASP22461
Docetaxel4
Gemcitabine3
Carboplatin2
Setidegrasib1
Cetuximab1
Leucovorin1
Oxaliplatin1
Fluorouracil1
Irinotecan1
Nanoparticle albumin-bound-paclitaxel1
Pembrolizumab1
Cisplatin1
Pemetrexed1
Liposomal Irinotecan1
ASP43961
ASP58341
panitumumab1
peficitinib11

Next readouts

  • 2023-12-25
  • 2026-05-31
  • 2027-04-30
  • 2027-06-30
  • 2028-11-30
  • 2028-12-31
  • 2030-02-28

Top conditions

  • Healthy34
  • Healthy Subjects29
  • Kidney Transplantation28
  • Overactive Bladder21
  • Type 2 Diabetes Mellitus20
  • Urinary Bladder, Overactive17
  • Liver Transplantation17
  • Healthy Volunteers17

Frequently asked questions about Astellas Pharma Inc

How many clinical trials does Astellas Pharma Inc have on ClinicalTrials.gov?
Astellas Pharma Inc is listed as the lead sponsor on 523 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
How many of Astellas Pharma Inc's trials are in Phase 3?
146 of Astellas Pharma Inc's trials are in Phase 3, spread across 26 active drug programs.
What therapeutic areas does Astellas Pharma Inc focus on?
Astellas Pharma Inc's most-studied conditions on ClinicalTrials.gov are Healthy, Healthy Subjects, Kidney Transplantation, Overactive Bladder, Type 2 Diabetes Mellitus.
When are Astellas Pharma Inc's next clinical trial readouts?
Astellas Pharma Inc has 7 upcoming primary-completion readouts tracked here; the soonest is “A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation”, expected around 2023-12-25.